Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CTP:phosphocholine cytidylyltransferase (CCT) is the rate-limiting enzyme in the CDP-choline pathway, also known as the Kennedy pathway, which is the primary route for the de novo synthesis of phosphatidylcholine (PC) in mammalian cells (UniProt P49585). As PC is the most abundant phospholipid in eukaryotic membranes, CCT is a critical regulator of membrane biogenesis, cell growth, and lipoprotein assembly (NCBI Gene PCYT1A). The enzyme}
Inhibition of the rate-limiting step in the Kennedy pathway (CDP-choline pathway) for phosphatidylcholine synthesis, leading to membrane disruption, impaired cell signaling, and induction of apoptosis (PubMed PMID: 11063872).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CTP:phosphocholine cytidylyltransferase (CCT) (CCT).